Long term data for a variety of hypofractionated definitive RT dose-fractionation schemes has matured, allowing patients and providers many standard-of-care options to choose from. Post-prostatectomy, adjuvant RT has largely been replaced by an early salvage approach. Multiparametric MRI and PSMA PET have enabled increasingly targeted RT delivery to the prostate and oligometastatic tumors. Areas of active investigation include determining the value of proton beam therapy and perirectal spacers, and optimally incorporate genomic tumor profiling and next generation hormonal therapies with RT in the curative setting. The use of radiation therapy to treat prostate cancer is rapidly evolving. In the coming years, there will be continued improvements in a variety of areas to enhance the value of RT in multidisciplinary prostate cancer management.
Keyphrases
- prostate cancer
- radiation therapy
- radical prostatectomy
- end stage renal disease
- ejection fraction
- locally advanced
- healthcare
- squamous cell carcinoma
- chronic kidney disease
- magnetic resonance imaging
- radiation induced
- quality improvement
- pet imaging
- early stage
- stem cells
- palliative care
- electronic health record
- skeletal muscle
- rectal cancer
- single cell
- metabolic syndrome
- dna methylation
- insulin resistance
- mesenchymal stem cells
- patient reported
- brain metastases